Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Angel Pharmaceuticals

Request full access

Clinical-stage cancer and autoimmune disease drug development.

Jiaxing, ChinaFounded 2020Biotech & Life Sciences

About Angel Pharmaceuticals

Angel Pharmaceuticals is a clinical-stage biopharmaceutical company established in 2020, focused on developing and commercializing a pipeline of targeted investigational medicines for cancer, autoimmune, and infectious diseases, primarily within Greater China. The company was co-founded by U.S.-based Corvus Pharmaceuticals (NASDAQ: CRVS) and a consortium of Chinese investors, including Puissance Capital, Hisun Pharmaceuticals, and Tigermed. This strategic collaboration enables the clinical development and commercialization of Corvus's drug pipeline in China. Angel Pharmaceuticals is headquartered in Jiaxing, China, with research and development facilities in both Jiaxing and Burlingame, California. The business model centers on in-licensing and advancing clinical-stage candidates. Angel licensed the rights from Corvus to develop and commercialize three assets in greater China: soquelitinib (an ITK inhibitor), ciforadenant (an adenosine A2A receptor antagonist), and mupadolimab (a monoclonal antibody targeting CD73). The company also obtained global rights to Corvus's preclinical BTK inhibitor programs. Corvus is the largest shareholder, holding a significant equity stake. One of Corvus's co-founders, Dr. Richard A. Miller, who previously co-founded IDEC (leading to the development of rituximab) and Pharmacyclics (known for ibrutinib), serves on Angel Pharmaceuticals' board. The company's lead asset, soquelitinib, is an oral small molecule designed to selectively inhibit ITK (interleukin-2-inducible T-cell kinase), an enzyme crucial for T-cell function. Angel is advancing soquelitinib in multiple trials in China, including a Phase 1b/2 trial for atopic dermatitis and a planned Phase 2 trial for asthma, with initial data from the dermatitis trial expected in late 2026. Other pipeline candidates include ciforadenant, being studied for renal cell carcinoma, and mupadolimab for solid tumors like non-small cell lung cancer. The company aims to make these innovative drugs more accessible to patients in the region.

Source: Dealroom company data

At a glance

Status
Operational
Employees
9
Open positions
1
Dealroom signal
56.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Oncology, Drug Development, Autoimmune
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jun 2026 $14M $55M Corvus Pharmaceuticals · TG Sino-Dragon Fund ↗
SERIES AOther financing Oct 2020 $41M $164M Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Angel Pharmaceuticals website traffic

Latest recorded traffic for Angel Pharmaceuticals is 950 monthly website visits.

Latest monthly visits950
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Angel Pharmaceuticals in the Jiaxing ecosystem

Live from Dealroom

The Angel Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Corvus Pharmaceuticals
  • TG Sino-Dragon Fund
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Jiaxing HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Angel Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Angel Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.